AdCD40L / Uppsala University - LARVOL DELTA

Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours (ESMO 2018) - P1/2; "Intratumoral injections of AdCD40L in combination with cyclophosphamide is feasible in patients with solid cancer. Desirable immune effects were noted and the potential of the treatment was also demonstrated in one patient who improved clinically."

Clinical • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Melanoma • Renal Cell Carcinoma

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up. (PubMed, Front Vet Sci) - "Our results suggest that local AdCD40L therapy is safe and could have beneficial effects in dogs, supporting further treatment development. Clinical translation to human patients is ongoing."

Journal • Gene Therapies • Immune Modulation • Inflammation • Melanoma • Oncology • Solid Tumor • CD40LG

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors. (PubMed, Cancer Gene Ther) - "In conclusion, gene therapy by repeated intratumoral AdCD40L injections alone, or in combination with cyclophosphamide, is feasible and safe in patients with solid cancers. The potential of intratumoral CD40L gene transfer as treatment of cancer was illustrated by the clinical improvement in two out of seven patients."

Clinical • Journal • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Gene Therapies • Genito-urinary Cancer • Immune Modulation • Inflammation • Melanoma • Oncology • Ovarian Cancer • Solid Tumor • Transplantation • Urothelial Cancer • CD40LG • CXCL8

Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. (PubMed, Sci Rep) - "F ADC ≥ 1 in both post-treatment scans and F D ≥ 1 at week 5 were related to a significant decrease of size of the injected lesions. These results suggest that in patients with MMM treated with AdCD40l, functional parameters of DW-MRI are better early predictors of OS than the established metabolic and morphologic criteria for FDG-PET/CT and MRI, respectively."

Clinical • Journal • Gene Therapies • Melanoma • Oncology • Solid Tumor

Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients (SITC 2017) - P1/2; "Importantly, IT rAdCD40L also augmented the activity of anti-PD-1.A sample size of 26 patients will have 75% power to detect an improvement from a null ORR of 33% to 55%, using a one group chi-square test and assuming a one-sided α–level of 5%. Immune analysis will be performed on pre and on-treatment tumor/liquid biopsies including but not limited to quantification of dendritic cells and T cells both in injected and non-injected tumors."

Checkpoint inhibition • Combination therapy • P1/2 data • Ocular Melanoma

Phase I/IIa AdCD40L immunogene therapy for malignant melanoma (clinicaltrials.gov) - P1/2, N=30; Recruiting; New P1/2 trial

New trial • Melanoma